Two injections, one key difference

Both are outpatient injections, both go into the hip joint under imaging guidance, and neither involves an operating theatre or a general anaesthetic. So what actually separates them?

The answer comes down to what each injection is trying to do inside the joint.

Hyaluronic acid (HA) works by supplementing the synovial fluid that has thinned or degraded with osteoarthritis. It restores viscosity, reduces friction between joint surfaces, and dampens some of the inflammatory activity driving pain. The cartilage structure itself is unchanged — HA manages symptoms rather than addressing the underlying tissue damage.

A ChondroFiller injection takes a different approach. It places an acellular collagen scaffold over a focal area of worn or damaged cartilage, creating a physical barrier that absorbs load while providing a matrix into which the patient's own stem cells can migrate and begin generating new tissue. The goal is regenerative, not palliative.

For a patient deciding between the two, that mechanistic difference maps directly onto the pattern of joint damage. Diffuse, widespread wear across the hip joint is broadly a better fit for HA's lubricating and anti-inflammatory effects. A distinct, focal cartilage defect with intact surrounding tissue is where ChondroFiller injection is designed to act. The right choice depends on what the hip's cartilage actually looks like — something only a clinical assessment and imaging can determine.

How ChondroFiller injection works in the hip

ChondroFiller injection is a CE-marked Class III medical device — not a drug, not a cell therapy, and not a surgical implant in the conventional sense. Its active component is an acellular, acid-extracted Type I collagen: the cells have been removed, leaving a pure structural protein matrix that the body recognises as its own.

When injected into the hip joint under ultrasound guidance, the collagen solution undergoes rapid in situ polymerisation — it self-gels within the joint space, adhering to the surface of the damaged cartilage and forming a three-dimensional scaffold. That scaffold acts as a chemotactic net: it signals to the patient's own progenitor cells — stem cells resident in surrounding tissue and synovial fluid — drawing them into the defect site. Once there, those recruited cells can differentiate into chondrocytes, the specialised cells responsible for producing cartilage matrix. Over time, the collagen scaffold is intended to be gradually replaced by newly generated tissue.

Two points are worth being precise about here. First, this is matrix-induced chondrogenesis, not guaranteed cartilage regrowth: the scaffold creates the conditions for repair; the extent of tissue maturation varies between patients and is not yet established by large independent hip-specific trials. Second, the procedure requires no operating theatre. Delivered under local anaesthesia with IV antibiotic cover and real-time ultrasound imaging, ChondroFiller injection is a single outpatient appointment — the imaging guidance ensures accurate placement over a focal Grade III or IV articular cartilage defect.

In the interim period while new tissue matures, the collagen gel also functions as a top-down mechanical cushion, absorbing load across worn hip articular surfaces and shielding remaining cartilage from further friction.

How hyaluronic acid injection works in the hip

Healthy synovial fluid owes its slippery, shock-absorbing character largely to hyaluronic acid — a long-chain glycosaminoglycan that averages around 7 MDa per molecule in a normal hip joint. In osteoarthritis, that molecular weight falls and the concentration drops, leaving joint fluid thinner and less able to protect the cartilage surfaces from friction and load.

An intra-articular HA injection replenishes this depleted environment. The injected gel restores the viscoelastic properties of synovial fluid, providing a cushioning layer between the femoral head and acetabulum that reduces cartilage-on-cartilage contact during movement. Beyond simple lubrication, HA also acts on the joint's biochemical environment: it may suppress pro-inflammatory cytokines and chemokines within the joint space, which may contribute to pain relief beyond the purely mechanical effect.

Not all HA formulations behave identically. Molecular weight influences how long the gel persists and how it interacts with joint tissue. Higher molecular weight preparations — typically 1,100–1,400 kDa — tend to provide more sustained lubrication than medium MW variants. A dynamic hybrid combining high MW and low MW HA fractions (80–100 kDa) has shown better outcomes for hip osteoarthritis than high MW HA alone in comparative studies, reflecting the fact that large and small HA fragments have distinct biological actions.

Several randomised controlled trials — including comparisons against corticosteroid and isotonic saline — support the clinical benefit of HA in hip osteoarthritis, and this evidence base underpins its established position in hip care pathways. The effect is temporary rather than permanent; depending on formulation, treatment may be a single injection or a short course of two to three, and can be repeated when symptoms return.

Which hip patients suit each injection

The single most useful question to ask is not 'which injection is newer?' but 'what does the damage in this particular hip actually look like?'

ChondroFiller injection is best matched to a focal cartilage lesion — a discrete patch of cartilage worn through to bone in one specific area of the hip joint (Grade III or IV on the ICRS scale), while the surrounding articular cartilage remains relatively intact. In that setting, the collagen scaffold has a defined zone to fill and a healthy border from which progenitor cells can migrate inward. A patient with a localised defect confirmed on MRI, combined with reasonable joint space elsewhere, is the kind of candidate the injection pathway is designed for. Suitability is assessed across four clinical dimensions — mechanics, joint chemistry, biological capacity, and timing — rather than any single scan finding, and there is no strict upper age limit.

Hyaluronic acid viscosupplementation suits a different picture: diffuse, generalised cartilage thinning across the hip joint surface, typically Kellgren–Lawrence Grade I to III osteoarthritis, where the predominant complaint is pain and stiffness rather than a mechanically distinct lesion. The HA gel restores lubrication across the whole joint environment rather than targeting one focal site.

Where these profiles diverge sharply: a patient with truly end-stage 'bone on bone' diffuse hip OA is unlikely to benefit from ChondroFiller's regenerative mechanism — there is no focal defect with healthy margins for the scaffold to work against — though HA may still offer some symptomatic relief in that context. Equally, a patient with a confirmed focal defect and otherwise preserved cartilage is an underpowered candidate for HA alone; lubrication cannot address a structural gap.

Both injections can sit within the same hip preservation pathway at different points — HA earlier for symptom management during diffuse low-grade OA, ChondroFiller injection when imaging and clinical assessment have identified a focal lesion appropriate for structural treatment. Determining which applies requires proper imaging and a specialist consultation, not self-assessment.

What the clinical evidence shows — and where the gaps are

The HA evidence in the hip joint is the more established of the two. The trials described in the previous section — Qvistgaard et al. (2006), Spitzer et al. (2010), and De Lucia et al. (2019) — collectively demonstrate reproducible symptom benefit across different formulations and dosing schedules. That body of work spans randomised controlled trials with active comparators and reflects a long clinical track record specifically in the hip.

ChondroFiller injection carries a different evidence profile. Hip-specific outcome data shows the modified Harris Hip Score improving by approximately 30 points over 12 months, with MOCART scores of 70–87 on MRI indicating good scaffold integration. Those are meaningful clinical signals. The important caveat is context: the larger volume of published outcome data originates from knee joint studies — where IKDC scores improve by approximately 30 points at 12 months — and from the manufacturer's Clinical Evaluation Report rather than independent, large-scale hip RCTs.

The most significant gap in the current evidence is direct comparison. No randomised controlled trial has yet compared ChondroFiller injection to hyaluronic acid injection in the hip joint. Any head-to-head efficacy claim between the two treatments at this stage is extrapolated, not directly evidenced. Long-term durability data for ChondroFiller injection in the hip beyond 12 to 24 months is also not yet established in the published independent literature.

Patients and clinicians should weigh this plainly: HA arrives with a deeper hip-specific trial record; ChondroFiller injection arrives with a different therapeutic aim — structural preservation rather than symptom management — and early outcome signals that are promising but call for further independent study.

Cost, access, and next steps at Lincolnshire Hip

Pulling the threads together: when a hip scan reveals a discrete focal lesion with intact surrounding cartilage, ChondroFiller injection is the more targeted option — a structural intervention aimed at the defect itself rather than the joint broadly. When the picture is diffuse, early-to-moderate cartilage thinning without a clearly bounded focal site, HA viscosupplementation is better matched to what the joint actually needs. For many patients the more useful question is not 'which of these two?' but 'where do I sit on the pathway?' — a specialist assessment may identify that a different injectable, or a combination approach, is the more appropriate route.

On funding and cost: HA viscosupplementation has a longer track record on the NHS and with private medical insurers, though NHS availability has become more variable. ChondroFiller injection is a self-funded private procedure; cost starts from £3,000 per hip, covering consultation, ultrasound, the product, the injection itself, IV antibiotic cover, and a six-week follow-up. It is not currently funded by the NHS or any private medical insurer.

Both options are available within the Lincolnshire Hip clinical pathway. Professor Paul Y.F. Lee provides ChondroFiller injection at outpatient clinics in Grantham and Sleaford; assessment begins with clinical consultation and imaging — typically MRI — to characterise the cartilage damage pattern before any recommendation is made.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.